FDA Biocompatibility & ISO 10993 Evaluation Guide

Start with the biological safety question

Biocompatibility is the evaluation of potential adverse biological responses arising from a medical device's contact with the body. An ISO 10993 test certificate alone does not establish the safety of every model or clinical use. Define the contact, materials and exposure first, then assemble the evidence supporting the finished device.

FDA's September 2023 ISO 10993-1 guidance addresses biological evaluation for direct and indirect body contact across 510(k), De Novo, PMA, IDE and HDE submissions. Start within the US regulatory pathway, with the intended use and device-specific guidance. A general material certificate cannot settle every product-specific question.

ISO 10993-1:2025: what FDA recognizes

As checked on October 15, 2026, FDA recognition 2-313 partially recognizes the sixth edition, ISO 10993-1:2025. It excludes the phrase “consumer products” in Clause 6.5.11.3 and Clause 6.9 on biological risk estimation. The recognition record also flags implementation questions, including some prolonged-contact genotoxicity assessments, for discussion with the review office.

FDA will accept premarket declarations of conformity to the previous recognition, 2-258 for the 2018 edition, until July 1, 2029; those declarations will not be accepted after that transition. This is a declaration transition, not a universal retest deadline or a promise that all existing reports satisfy a new device's needs. Confirm the live record when planning and filing.

Use our recognized standards and declaration guide to distinguish a formal declaration from justified general use of a standard. Record the edition, recognition number, recognized scope and any supplementary evidence.

Build a biological evaluation plan before ordering tests

FDA's endpoint tables provide an evaluation framework rather than a universal testing checklist. Address the relevant endpoints through suitable existing evidence, additional testing or a documented justification. Device-specific risks can require more or fewer assessments than a table alone suggests.

Use consistent contact terminology; the FDA biocompatibility glossary explains exposure duration and the terminology retained in its guidance. Reconcile intermittent or repeated contact with the actual use pattern rather than copying the duration from a similar product.

Choose representative test articles and justify differences

Describe the final marketed configuration, including manufacture, cleaning, sterilization and packaging where relevant. Identify which models, accessories, material combinations and processing conditions the evaluation covers. A raw resin sample, an unfinished prototype or a report on a predecessor device needs a defensible bridge to the finished product.

For outsourced work, agree the test article, extraction approach, methods, acceptance criteria, deviations and reporting deliverables with qualified specialists before commissioning the study. Retain the rationale for any worst-case sample and differences from the released configuration. Chemical characterization and toxicological assessment should address the exposure question and identified uncertainties; they are not automatic substitutes for every biological endpoint.

FDA's September 2026 risk-assessment town hall discusses risk-based approaches with examples for material-mediated pyrogenicity and systemic endpoints. Use the examples to examine the strength of the device-specific reasoning, rather than treating a worked example as a blanket testing exemption.

Bioburden, endotoxin and material-mediated pyrogenicity

These assessments answer different questions. Keep their protocols and conclusions connected, while making each evidence claim explicit.

Follow the applicable FDA sterile-device submission guidance for sterilization and pyrogenicity information. Evaluate the basis for a “non-pyrogenic” label separately. Avoid assuming that changes in ISO terminology, a sterilization method or a single negative test remove the need to address the relevant biological risk.

Turn the evaluation into submission-ready evidence

For a 510(k), De Novo or PMA, keep a traceable account of the device, contact category, endpoints, supporting evidence and overall conclusion. In eSTAR, make the attachments and answers consistent with the evaluated device; completing a template does not resolve a missing scientific justification.

A useful evidence index identifies each report's revision, tested configuration, endpoint, limitations and location. Explain comparisons to previously evaluated devices and address gaps explicitly. Use a focused Pre-Submission where the proposed approach, novel materials or interpretation of recognition limitations needs agency feedback before a major study commitment.

Maintain the evaluation after design transfer

Connect biological evaluation records to QMSR design and change controls. Review changes to materials, suppliers, processing, sterilization, packaging, intended contact or clinical use for their effect on the existing safety conclusion. Assign a reviewer and retain the decision to leverage evidence, update the assessment or generate new data.

Pure Global can support regulatory gap assessment and submission planning, coordinating the evidence strategy with the manufacturer and qualified laboratory or toxicology specialists. The manufacturer remains responsible for the device and its records; FDA determines whether the submitted evidence supports the requested authorization.